IMATINIB MESYLATE
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (L01E, L01EA) — coverage varies; not interchangeable
- Bosutinib (Bosulif): not a benefit
- Dasatinib (Sprycel): not a benefit
- Nilotinib (Tasigna): not a benefit
- Afatinib (Giotrif): not a benefit
- Erlotinib (Tarceva): not a benefit
- Gefitinib (Iressa): not a benefit
2 more in the class list below
Ach-Imatinib · DIN 02490986 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Imatinib · DIN 02490986
Manufacturer: Accord Healthcare Inc.; listing date 2021-01-29
Health Canada: Marketed since 2020-11-24 · brand ACH-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Accord healthcare inc · schedule Prescription
Ach-Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98101 · Verify on the e-Formulary ↗ (DIN 02490986)
Source record
DIN 02490986: Ach-Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id ACH
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490986
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98101
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: active shortage (reported 2024-03-22, last updated 2024-03-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02490986
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Imatinib · DIN 02355337 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Imatinib · DIN 02355337
Manufacturer: Apotex Inc.; listing date 2013-05-31
Health Canada: Marketed since 2013-04-19 · brand APO-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Apotex inc · schedule Prescription
Apo-Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84058 · Verify on the e-Formulary ↗ (DIN 02355337)
Source record
DIN 02355337: Apo-Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id APX
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02355337
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84058
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: resolved shortage (ended 2025-01-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02355337
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gleevec · DIN 02253275 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gleevec · DIN 02253275
Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02
Health Canada: Marketed since 2005-04-05 · brand GLEEVEC · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824 · Verify on the e-Formulary ↗ (DIN 02253275)
Source record
DIN 02253275: Gleevec
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id NOV
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $29.7475; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02253275
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02253275
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Imatinib · DIN 02504596 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Imatinib · DIN 02504596
Manufacturer: Sanis Health Inc.; listing date 2021-05-31
Health Canada: Marketed since 2021-04-07 · brand IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Sanis health inc · schedule Prescription
Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99400 · Verify on the e-Formulary ↗ (DIN 02504596)
Source record
DIN 02504596: Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id SAI
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504596
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99400
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: resolved shortage (ended 2025-11-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504596
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Imatinib · DIN 02521202 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Imatinib · DIN 02521202
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-05-31
Health Canada: Marketed since 2024-04-29 · brand IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101043 · Verify on the e-Formulary ↗ (DIN 02521202)
Source record
DIN 02521202: Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id SIV
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521202
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101043
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02521202
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Imatinib · DIN 02492334 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Imatinib · DIN 02492334
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-06-19 · brand MINT-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98235 · Verify on the e-Formulary ↗ (DIN 02492334)
Source record
DIN 02492334: Mint-Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id MIN
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492334
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98235
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02492334
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nat-Imatinib · DIN 02397285 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Nat-Imatinib · DIN 02397285
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2014-06-26
Health Canada: Marketed since 2017-08-11 · brand NAT-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88225 · Verify on the e-Formulary ↗ (DIN 02397285)
Source record
DIN 02397285: Nat-Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id NAT
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397285
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88225
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: resolved shortage (ended 2025-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397285
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Imatinib · DIN 02399806 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Imatinib · DIN 02399806
Manufacturer: Teva Canada Limited; listing date 2013-05-31
Health Canada: Marketed since 2013-04-02 · brand TEVA-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Teva canada limited · schedule Prescription
Teva-Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88465 · Verify on the e-Formulary ↗ (DIN 02399806)
Source record
DIN 02399806: Teva-Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id TEV
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399806
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88465
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Shortage status: resolved shortage (ended 2025-05-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399806
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Imatinib · DIN 02490994 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Imatinib · DIN 02490994
Manufacturer: Accord Healthcare Inc.; listing date 2021-01-29
Health Canada: Marketed since 2020-11-24 · brand ACH-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Accord healthcare inc · schedule Prescription
Ach-Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98102 · Verify on the e-Formulary ↗ (DIN 02490994)
Source record
DIN 02490994: Ach-Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id ACH
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490994
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98102
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: active shortage (reported 2024-03-22, last updated 2024-03-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02490994
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Imatinib · DIN 02355345 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Imatinib · DIN 02355345
Manufacturer: Apotex Inc.; listing date 2013-05-31
Health Canada: Marketed since 2013-04-19 · brand APO-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Apotex inc · schedule Prescription
Apo-Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84059 · Verify on the e-Formulary ↗ (DIN 02355345)
Source record
DIN 02355345: Apo-Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id APX
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02355345
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84059
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: shortage reported ended 2026-07-16 (report last updated 2026-07-16); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02355345
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gleevec · DIN 02253283 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gleevec · DIN 02253283
Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02
Health Canada: Marketed since 2004-10-25 · brand GLEEVEC · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73825 · Verify on the e-Formulary ↗ (DIN 02253283)
Source record
DIN 02253283: Gleevec
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id NOV
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $118.9900; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02253283
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73825
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02253283
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Imatinib · DIN 02504618 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Imatinib · DIN 02504618
Manufacturer: Sanis Health Inc.; listing date 2021-05-31
Health Canada: Marketed since 2021-04-07 · brand IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Sanis health inc · schedule Prescription
Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99401 · Verify on the e-Formulary ↗ (DIN 02504618)
Source record
DIN 02504618: Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id SAI
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504618
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99401
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: resolved shortage (ended 2025-11-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504618
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Imatinib · DIN 02521210 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Imatinib · DIN 02521210
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-05-31
Health Canada: Marketed since 2024-04-29 · brand IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101045 · Verify on the e-Formulary ↗ (DIN 02521210)
Source record
DIN 02521210: Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id SIV
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521210
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101045
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02521210
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Imatinib · DIN 02492342 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Imatinib · DIN 02492342
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-06-19 · brand MINT-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98236 · Verify on the e-Formulary ↗ (DIN 02492342)
Source record
DIN 02492342: Mint-Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id MIN
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492342
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98236
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02492342
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nat-Imatinib · DIN 02397293 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Nat-Imatinib · DIN 02397293
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2014-06-26
Health Canada: Marketed since 2017-08-11 · brand NAT-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88226 · Verify on the e-Formulary ↗ (DIN 02397293)
Source record
DIN 02397293: Nat-Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id NAT
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397293
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88226
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: resolved shortage (ended 2025-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397293
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Imatinib · DIN 02399814 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Imatinib · DIN 02399814
Manufacturer: Teva Canada Limited; listing date 2013-05-31
Health Canada: Marketed since 2013-05-22 · brand TEVA-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Teva canada limited · schedule Prescription
Teva-Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88466 · Verify on the e-Formulary ↗ (DIN 02399814)
Source record
DIN 02399814: Teva-Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id TEV
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399814
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88466
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Shortage status: resolved shortage (ended 2021-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399814
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Imatinib · DIN 02495066 · 100mg · tablet
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Imatinib · DIN 02495066
Manufacturer: Jamp Pharma Corporation; listing date 2021-06-30
Health Canada: Dormant since 2025-07-31 · brand JAMP IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98501 · Verify on the e-Formulary ↗ (DIN 02495066)
Source record
DIN 02495066: Jamp Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id JPC
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495066
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98501
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
PMS-Imatinib · DIN 02431114 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495066
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.
PMS-Imatinib · DIN 02431114 · 100mg · tablet
General benefitDormant since 2020-07-24 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Imatinib · DIN 02431114
Manufacturer: Pharmascience Inc.; listing date 2015-07-29
Health Canada: Dormant since 2020-07-24 · brand PMS-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 100 MG · company Pharmascience inc · schedule Prescription
PMS-Imatinib: Formulary list price $5.2079/unit (unit not stated in source; not the patient's cost)
Ministry pays: $5.2079 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91555 · Verify on the e-Formulary ↗ (DIN 02431114)
Source record
DIN 02431114: PMS-Imatinib
Raw flags: sec3=Y
Item: 100000180; group id 168; item number 0284; lccId None; manufacturer id PMS
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $5.2079; ministry $5.2079
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02431114
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91555
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490986 · $5.2079
Apo-Imatinib · DIN 02355337 · $5.2079
Gleevec · DIN 02253275 · $5.2079
Imatinib · DIN 02504596 · $5.2079
Imatinib · DIN 02521202 · $5.2079
Jamp Imatinib · DIN 02495066 · $5.2079
Mint-Imatinib · DIN 02492334 · $5.2079
Nat-Imatinib · DIN 02397285 · $5.2079
Teva-Imatinib · DIN 02399806 · $5.2079
Shortage status: active shortage (reported 2021-11-14, last updated 2021-11-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02431114
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-07-24 — choose a marketed DIN from the same-category list.
Jamp Imatinib · DIN 02495074 · 400mg · tablet
General benefitDormant since 2025-07-31 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Imatinib · DIN 02495074
Manufacturer: Jamp Pharma Corporation; listing date 2021-06-30
Health Canada: Dormant since 2025-07-31 · brand JAMP IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Jamp pharma corporation · schedule Prescription
Jamp Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98502 · Verify on the e-Formulary ↗ (DIN 02495074)
Source record
DIN 02495074: Jamp Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id JPC
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495074
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98502
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
PMS-Imatinib · DIN 02431122 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495074
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.
PMS-Imatinib · DIN 02431122 · 400mg · tablet
General benefitDormant since 2018-05-16 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Imatinib · DIN 02431122
Manufacturer: Pharmascience Inc.; listing date 2015-07-29
Health Canada: Dormant since 2018-05-16 · brand PMS-IMATINIB · ATC L01EA01 IMATINIB · form Tablet · route Oral · ingredients IMATINIB (IMATINIB MESYLATE) 400 MG · company Pharmascience inc · schedule Prescription
PMS-Imatinib: Formulary list price $20.8314/unit (unit not stated in source; not the patient's cost)
Ministry pays: $20.8314 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91556 · Verify on the e-Formulary ↗ (DIN 02431122)
Source record
DIN 02431122: PMS-Imatinib
Raw flags: sec3=Y
Item: 100000177; group id 168; item number 0285; lccId None; manufacturer id PMS
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $20.8314; ministry $20.8314
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02431122
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91556
Therapeutic Notes (formulary)
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
Interchangeable products
Ach-Imatinib · DIN 02490994 · $20.8314
Apo-Imatinib · DIN 02355345 · $20.8314
Gleevec · DIN 02253283 · $20.8314
Imatinib · DIN 02504618 · $20.8314
Imatinib · DIN 02521210 · $20.8314
Jamp Imatinib · DIN 02495074 · $20.8314
Mint-Imatinib · DIN 02492342 · $20.8314
Nat-Imatinib · DIN 02397293 · $20.8314
Teva-Imatinib · DIN 02399814 · $20.8314
Shortage status: active shortage (reported 2021-11-14, last updated 2021-11-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02431122
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2018-05-16 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered
Matched class: 10:00 ANTINEOPLASTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE
Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE
10:00 ANTINEOPLASTIC AGENTS
· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 500mg · Tab
· 33 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 50mg, 70mg, 80mg, 100mg, 140mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 150mg, 200mg · Cap
· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 30mg, 40mg · Tab
· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 100mg, 150mg · Tab
· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg · Tab
· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 75mg, 100mg, 125mg · Tab
· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 200mg · Tab
· 18 products · General benefit · strengths: 250mg, 500mg · Tab
· 1 products · General benefit · strengths: 50mg · Cap
· 17 products · General benefit · strengths: 1mg · Tab
· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00
and 34 more